Iota-carrageenan neutralizes SARS-CoV-2 and inhibits viral replication in vitro

PLoS One. 2021 Feb 17;16(2):e0237480. doi: 10.1371/journal.pone.0237480. eCollection 2021.

Abstract

In the absence of a vaccine and other effective prophylactic or therapeutic countermeasures the severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) remains a significant public health threat. Attachment and entry of coronaviruses including SARS-CoV-2 is mainly mediated by the spike glycoprotein. Here, we show that iota-carrageenan can inhibit the cell entry of the SARS-CoV-2 spike pseudotyped lentivirus in a dose dependent manner. SARS-CoV-2 spike pseudotyped lentivirus particles were efficiently neutralized with an IC50 value of 2.6 μg/ml iota-carrageenan. Experiments with patient isolated wild type SARS-CoV-2 virus showed an inhibition of replication in a similar range. In vitro data on iota-carrageenan against various Rhino- and endemic Coronaviruses showed similar IC50 values and translated readily into clinical effectiveness when a nasal spray containing iota-carrageenan demonstrated a reduction of severity and duration of symptoms of common cold caused by various respiratory viruses. Accordingly, our in vitro data on SARS-CoV-2 spike pseudotyped lentivirus and replication competent SARS-CoV-2 suggest that administration of iota-carrageenan may be an effective and safe prophylaxis or treatment for SARS-CoV-2 infections.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Viral / immunology
  • Antiviral Agents / pharmacology
  • COVID-19 / immunology
  • COVID-19 / metabolism
  • COVID-19 / virology*
  • COVID-19 Drug Treatment
  • Carrageenan / pharmacology*
  • Chlorocebus aethiops
  • HEK293 Cells
  • Humans
  • Lentivirus / metabolism
  • Middle Aged
  • SARS-CoV-2 / drug effects*
  • SARS-CoV-2 / physiology
  • Spike Glycoprotein, Coronavirus / immunology
  • Spike Glycoprotein, Coronavirus / metabolism
  • Vero Cells
  • Virus Internalization / drug effects
  • Virus Replication / drug effects*

Substances

  • Antibodies, Viral
  • Antiviral Agents
  • Spike Glycoprotein, Coronavirus
  • spike protein, SARS-CoV-2
  • Carrageenan

Grants and funding

This work was co-funded by the Austrian Science Promotion Agency (FFG) project number 880687 (https://www.ffg.at). Marinomed Biotech AG (www.marinomed.com) provided support in form of salaries for all authors employed by Marinomed Biotech AG. Marinomed Biotech AG had a role in study design, data collection and analysis, decision to publish, preparation of the manuscript and financing the processing charge of the manuscript. This work was supported by graduate program GRK 2504 from the German Research Council to U.S., and it was performed in partial fulfillment of the requirements for obtaining Dr. med. Degree at the Friedrich-Alexander University Erlangen-Nürnberg for J.A. and M.F..